The biannual injection for osteoporosis is denosumab (brand name Prolia), a 60 mg shot given under the skin once every six months. It works by blocking a protein called RANKL, which osteoclasts need to form and break down bone. By slowing bone loss, it increases bone density and lowers the risk of spine, hip and other fractures. Its main benefits are convenience and effectiveness; its main caution is that doses must stay on schedule, because stopping abruptly causes rapid bone loss.
For many patients, taking a weekly tablet on an empty stomach and staying upright afterward is a real burden. An injection for osteoporosis every six months removes that daily or weekly routine, and in my practice this is often what makes long-term treatment possible.
How Osteoporosis Develops
Bone is living tissue that is constantly rebuilt. Osteoclasts remove old bone, and osteoblasts replace it. Osteoporosis develops when removal outpaces replacement, so bone becomes thinner and its internal honeycomb structure weakens.
In primary osteoporosis, the main drivers are aging and the fall in estrogen after menopause, along with genetics. Secondary osteoporosis results from another condition or medicine, such as long-term glucocorticoid use, hyperparathyroidism, malabsorption, low testosterone or certain cancer treatments. Other risk factors include low body weight, smoking, heavy alcohol use, inactivity and a parent who broke a hip.
How the Biannual Injection Works
Osteoclasts develop when RANKL, released by bone-forming cells, binds to a receptor called RANK on osteoclast precursors. Denosumab is a monoclonal antibody that attaches to RANKL and stops it from binding. The body’s own natural brake on this system, osteoprotegerin, works in a similar way.
With RANKL blocked, fewer osteoclasts form and existing ones become less active. Bone resorption drops quickly, and because osteoblasts keep working, bone density gradually rises in the spine and hip.
Why every six months?
After an injection, denosumab levels stay high enough to suppress osteoclasts for about six months. Unlike bisphosphonates, it does not bind into the bone itself, so its effect fades once the drug is cleared. That is why the schedule matters so much.
Benefits and How It Compares
Denosumab reduces the risk of vertebral, hip and non-vertebral fractures in postmenopausal women with osteoporosis, and it is also used in men and in glucocorticoid-induced osteoporosis. Because it is not cleared by the kidneys, it can be an option for some people whose kidney function rules out bisphosphonates, although they need close calcium monitoring.
| Treatment | How often | How it works | Key point |
|---|---|---|---|
| Oral bisphosphonates (alendronate, risedronate) | Weekly or monthly tablet | Bind to bone and inhibit osteoclasts | Strict dosing rules; stomach irritation possible |
| Zoledronic acid | Yearly infusion | Bisphosphonate given intravenously | Long-lasting; flu-like reaction after first dose is common |
| Denosumab | Every 6 months, injection | Blocks RANKL | Must not be stopped without a follow-on plan |
| Teriparatide / abaloparatide | Daily injection | Stimulate bone formation | Used for high fracture risk; limited treatment duration |
| Romosozumab | Monthly injection for 12 months | Builds bone and reduces resorption | For very high fracture risk; not for those with recent heart attack or stroke |
Who Is a Candidate?
Diagnosis starts with a DXA scan of the hip and spine. A T-score of -2.5 or lower, or a low-trauma fracture of the hip or spine, indicates osteoporosis. Doctors combine the scan with a fracture risk assessment, such as FRAX, to decide who needs medicine.
Denosumab is often chosen for people at high fracture risk, those who cannot tolerate or absorb oral bisphosphonates, those with reduced kidney function, and those who value an infrequent schedule. Before starting, blood tests check calcium, vitamin D, kidney function and look for secondary causes.
Calcium and vitamin D
Adequate calcium and vitamin D are essential, because denosumab can lower blood calcium. Most patients take them through diet and, where needed, supplements. Our article on the role of supplements in osteoporosis management explains how much is usually recommended.
Side Effects and Safety
Most people tolerate the injection well. Known side effects include:
- Low blood calcium (hypocalcemia), especially in people with severe kidney disease or low vitamin D
- Skin reactions such as eczema, and occasionally skin infections like cellulitis
- Back, joint or muscle pain
- Osteonecrosis of the jaw, a rare problem with jaw healing, more likely after dental extractions
- Atypical femoral fractures, rare thigh-bone fractures seen with long-term use of bone-resorption blockers
Tell your dentist you are on denosumab, and aim to complete major dental work before starting where possible.
The rebound effect after stopping
This is the most important safety point. If a dose is delayed well beyond six months or treatment stops without a plan, osteoclast activity rebounds, bone density falls rapidly, and some people develop multiple vertebral fractures. Anyone stopping denosumab should usually move to a bisphosphonate, and doses should be booked no later than a few weeks after the six-month mark.
Future Directions
Current work focuses on practical questions rather than new drugs. These include the best way to transition off denosumab, how long treatment should last, and how to sequence therapies. There is growing agreement that people at very high risk may benefit from starting with a bone-building agent, then continuing with an antiresorptive such as denosumab to maintain the gains. Biosimilar versions of denosumab are also becoming available, which may improve access.
Because bone and marrow share the same space, some of our readers also follow hematological conditions that affect the skeleton, such as myeloma. For those topics, see our guide to blood disorders, and for broader bone health, our osteoporosis guide.
When to See a Doctor
Contact your doctor if you:
- Have missed or delayed a denosumab dose
- Develop muscle cramps, tingling around the mouth or in the fingers, which can signal low calcium
- Notice new thigh or groin pain, or jaw pain, exposed bone or poor healing after dental work
- Have sudden back pain or height loss, which can reflect a vertebral fracture
- Are considering stopping treatment for any reason
Frequently Asked Questions
How long can I stay on the biannual injection?
There is no fixed maximum, and some people continue for many years under regular review. The decision depends on fracture risk, bone density response and side effects, and any plan to stop must include a follow-on medicine.
What happens if I miss a dose?
Have the injection as soon as possible and resume the six-month schedule from that date. A long delay increases the risk of rebound bone loss and vertebral fractures, so do not wait for the next routine appointment.
Is denosumab better than bisphosphonate tablets?
Both reduce fractures. Denosumab tends to increase bone density more and suits people who cannot take tablets correctly or have kidney problems, while bisphosphonates have a lasting effect that allows drug holidays. The right choice depends on your individual situation.
Can men use the six-monthly injection?
Yes. Denosumab is approved for men with osteoporosis and for bone loss related to certain hormone treatments for prostate cancer.
Key Takeaways
- The biannual injection for osteoporosis is denosumab, a RANKL-blocking antibody given every six months.
- It reduces bone breakdown, raises bone density and lowers fracture risk.
- Calcium and vitamin D levels must be adequate before and during treatment.
- Stopping or delaying doses can trigger rapid bone loss and spine fractures, so a transition plan is essential.
- Research is refining treatment sequencing and how best to come off therapy.
